Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation

T. Mori, S. Mori, Y. Kanda, K. Yakushiji, Shin Mineishi, Y. Takaue, H. Gondo, M. Harada, H. Sakamaki, T. Yajima, Y. Iwao, T. Hibi, S. Okamoto

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

To evaluate the clinical significance of a cytomegalovirus (CMV) antigenemia assay in the prediction and diagnosis of CMV gastrointestinal (CMV-GI) disease after hematopoietic stem cell transplantation (HSCT), 19 allogeneic HSCT recipients developing CMV-GI disease were retrospectively reviewed. All patients were monitored by a CMV antigenemia assay, at least once weekly after engraftment. The median onset of CMV-GI disease occurred 31 days post transplant (range: 19-62). Only four of 19 patients (21%) developed a positive CMV antigenemia test before developing CMV-GI diseases. Although all 19 patients subsequently developed positive CNIV antigenemia tests during their clinical courses, the values remained at a low-level in nine (47%) patients. Among the 14 patients in whom results of real-time polymerase chain reaction (PCR) were available, seven (50%) yielded positive results of real-time PCR before developing CMV-GI disease. In contrast to the values of CMV antigenemia, all 14 patients exclusively yielded high viral loads (median: 2.8 × 104 copies/ml plasma). We conclude that CMV antigenemia testing has limited value in prediction or early diagnosis of CMV-GI disease, and that real-time PCR could have a more diagnostic significance.

Original languageEnglish (US)
Pages (from-to)431-434
Number of pages4
JournalBone Marrow Transplantation
Volume33
Issue number4
DOIs
StatePublished - Feb 1 2004

Fingerprint

Gastrointestinal Diseases
Hematopoietic Stem Cell Transplantation
Cytomegalovirus
Real-Time Polymerase Chain Reaction
Viral Load
Early Diagnosis
Transplants

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Mori, T. ; Mori, S. ; Kanda, Y. ; Yakushiji, K. ; Mineishi, Shin ; Takaue, Y. ; Gondo, H. ; Harada, M. ; Sakamaki, H. ; Yajima, T. ; Iwao, Y. ; Hibi, T. ; Okamoto, S. / Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. In: Bone Marrow Transplantation. 2004 ; Vol. 33, No. 4. pp. 431-434.
@article{f91457c15450488a8d116328ecc20a93,
title = "Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation",
abstract = "To evaluate the clinical significance of a cytomegalovirus (CMV) antigenemia assay in the prediction and diagnosis of CMV gastrointestinal (CMV-GI) disease after hematopoietic stem cell transplantation (HSCT), 19 allogeneic HSCT recipients developing CMV-GI disease were retrospectively reviewed. All patients were monitored by a CMV antigenemia assay, at least once weekly after engraftment. The median onset of CMV-GI disease occurred 31 days post transplant (range: 19-62). Only four of 19 patients (21{\%}) developed a positive CMV antigenemia test before developing CMV-GI diseases. Although all 19 patients subsequently developed positive CNIV antigenemia tests during their clinical courses, the values remained at a low-level in nine (47{\%}) patients. Among the 14 patients in whom results of real-time polymerase chain reaction (PCR) were available, seven (50{\%}) yielded positive results of real-time PCR before developing CMV-GI disease. In contrast to the values of CMV antigenemia, all 14 patients exclusively yielded high viral loads (median: 2.8 × 104 copies/ml plasma). We conclude that CMV antigenemia testing has limited value in prediction or early diagnosis of CMV-GI disease, and that real-time PCR could have a more diagnostic significance.",
author = "T. Mori and S. Mori and Y. Kanda and K. Yakushiji and Shin Mineishi and Y. Takaue and H. Gondo and M. Harada and H. Sakamaki and T. Yajima and Y. Iwao and T. Hibi and S. Okamoto",
year = "2004",
month = "2",
day = "1",
doi = "10.1038/sj.bmt.1704369",
language = "English (US)",
volume = "33",
pages = "431--434",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. / Mori, T.; Mori, S.; Kanda, Y.; Yakushiji, K.; Mineishi, Shin; Takaue, Y.; Gondo, H.; Harada, M.; Sakamaki, H.; Yajima, T.; Iwao, Y.; Hibi, T.; Okamoto, S.

In: Bone Marrow Transplantation, Vol. 33, No. 4, 01.02.2004, p. 431-434.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation

AU - Mori, T.

AU - Mori, S.

AU - Kanda, Y.

AU - Yakushiji, K.

AU - Mineishi, Shin

AU - Takaue, Y.

AU - Gondo, H.

AU - Harada, M.

AU - Sakamaki, H.

AU - Yajima, T.

AU - Iwao, Y.

AU - Hibi, T.

AU - Okamoto, S.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - To evaluate the clinical significance of a cytomegalovirus (CMV) antigenemia assay in the prediction and diagnosis of CMV gastrointestinal (CMV-GI) disease after hematopoietic stem cell transplantation (HSCT), 19 allogeneic HSCT recipients developing CMV-GI disease were retrospectively reviewed. All patients were monitored by a CMV antigenemia assay, at least once weekly after engraftment. The median onset of CMV-GI disease occurred 31 days post transplant (range: 19-62). Only four of 19 patients (21%) developed a positive CMV antigenemia test before developing CMV-GI diseases. Although all 19 patients subsequently developed positive CNIV antigenemia tests during their clinical courses, the values remained at a low-level in nine (47%) patients. Among the 14 patients in whom results of real-time polymerase chain reaction (PCR) were available, seven (50%) yielded positive results of real-time PCR before developing CMV-GI disease. In contrast to the values of CMV antigenemia, all 14 patients exclusively yielded high viral loads (median: 2.8 × 104 copies/ml plasma). We conclude that CMV antigenemia testing has limited value in prediction or early diagnosis of CMV-GI disease, and that real-time PCR could have a more diagnostic significance.

AB - To evaluate the clinical significance of a cytomegalovirus (CMV) antigenemia assay in the prediction and diagnosis of CMV gastrointestinal (CMV-GI) disease after hematopoietic stem cell transplantation (HSCT), 19 allogeneic HSCT recipients developing CMV-GI disease were retrospectively reviewed. All patients were monitored by a CMV antigenemia assay, at least once weekly after engraftment. The median onset of CMV-GI disease occurred 31 days post transplant (range: 19-62). Only four of 19 patients (21%) developed a positive CMV antigenemia test before developing CMV-GI diseases. Although all 19 patients subsequently developed positive CNIV antigenemia tests during their clinical courses, the values remained at a low-level in nine (47%) patients. Among the 14 patients in whom results of real-time polymerase chain reaction (PCR) were available, seven (50%) yielded positive results of real-time PCR before developing CMV-GI disease. In contrast to the values of CMV antigenemia, all 14 patients exclusively yielded high viral loads (median: 2.8 × 104 copies/ml plasma). We conclude that CMV antigenemia testing has limited value in prediction or early diagnosis of CMV-GI disease, and that real-time PCR could have a more diagnostic significance.

UR - http://www.scopus.com/inward/record.url?scp=12144288318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144288318&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704369

DO - 10.1038/sj.bmt.1704369

M3 - Article

C2 - 14676775

AN - SCOPUS:12144288318

VL - 33

SP - 431

EP - 434

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -